JP2011518836A5 - - Google Patents

Download PDF

Info

Publication number
JP2011518836A5
JP2011518836A5 JP2011506453A JP2011506453A JP2011518836A5 JP 2011518836 A5 JP2011518836 A5 JP 2011518836A5 JP 2011506453 A JP2011506453 A JP 2011506453A JP 2011506453 A JP2011506453 A JP 2011506453A JP 2011518836 A5 JP2011518836 A5 JP 2011518836A5
Authority
JP
Japan
Prior art keywords
chloro
docosa
nonaen
tetraazatetracyclo
pentaazatetracyclo
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2011506453A
Other languages
English (en)
Japanese (ja)
Other versions
JP2011518836A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2009/041555 external-priority patent/WO2009132202A2/en
Publication of JP2011518836A publication Critical patent/JP2011518836A/ja
Publication of JP2011518836A5 publication Critical patent/JP2011518836A5/ja
Pending legal-status Critical Current

Links

JP2011506453A 2008-04-24 2009-04-23 大環状化合物およびそれらのキナーゼ阻害剤としての使用 Pending JP2011518836A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US4754708P 2008-04-24 2008-04-24
US61/047,547 2008-04-24
US12258208P 2008-12-15 2008-12-15
US61/122,582 2008-12-15
PCT/US2009/041555 WO2009132202A2 (en) 2008-04-24 2009-04-23 Macrocyclic compounds and their use as kinase inhibitors

Publications (2)

Publication Number Publication Date
JP2011518836A JP2011518836A (ja) 2011-06-30
JP2011518836A5 true JP2011518836A5 (enExample) 2012-06-14

Family

ID=41100487

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2011506453A Pending JP2011518836A (ja) 2008-04-24 2009-04-23 大環状化合物およびそれらのキナーゼ阻害剤としての使用

Country Status (5)

Country Link
US (1) US8871753B2 (enExample)
EP (1) EP2274288A2 (enExample)
JP (1) JP2011518836A (enExample)
CA (1) CA2722326A1 (enExample)
WO (1) WO2009132202A2 (enExample)

Families Citing this family (81)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG10201510696RA (en) 2008-06-27 2016-01-28 Celgene Avilomics Res Inc Heteroaryl compounds and uses thereof
US11351168B1 (en) 2008-06-27 2022-06-07 Celgene Car Llc 2,4-disubstituted pyrimidines useful as kinase inhibitors
US8338439B2 (en) 2008-06-27 2012-12-25 Celgene Avilomics Research, Inc. 2,4-disubstituted pyrimidines useful as kinase inhibitors
AU2013202496B2 (en) * 2008-06-27 2016-08-04 Celgene Car Llc Heteroaryl compounds and uses thereof
AU2009288021B2 (en) 2008-09-08 2015-06-18 Merck Patent Gmbh Macrocyclics pyrimidines as Aurora kinase inhibitors
WO2010085597A1 (en) * 2009-01-23 2010-07-29 Incyte Corporation Macrocyclic compounds and their use as kinase inhibitors
JP5918693B2 (ja) 2009-05-05 2016-05-18 ダナ ファーバー キャンサー インスティテュート インコーポレイテッド Ｅｇｆｒ阻害剤及び疾患の治療方法
TW201100441A (en) 2009-06-01 2011-01-01 Osi Pharm Inc Amino pyrimidine anticancer compounds
US8445490B2 (en) 2009-10-14 2013-05-21 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis C
US8586584B2 (en) * 2009-10-14 2013-11-19 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis C
HU0900798D0 (en) * 2009-12-21 2010-03-01 Vichem Chemie Kutato Kft 4-phenylamino-pyrimidine derivatives having protein kinase inhibitor activity
WO2011139513A1 (en) * 2010-05-04 2011-11-10 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis c
TWI513694B (zh) * 2010-05-11 2015-12-21 Amgen Inc 抑制間變性淋巴瘤激酶的嘧啶化合物
WO2012019132A2 (en) 2010-08-06 2012-02-09 Cell Signaling Technology, Inc. Anaplastic lymphoma kinase in kidney cancer
MY160734A (en) 2010-08-10 2017-03-15 Celgene Avilomics Res Inc Besylate salt of a btk inhibitor
US8765944B2 (en) 2010-08-19 2014-07-01 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis C
NZ710636A (en) 2010-11-01 2017-02-24 Celgene Avilomics Res Inc Heterocyclic compounds and uses thereof
WO2012061303A1 (en) 2010-11-01 2012-05-10 Avila Therapeutics, Inc. Heteroaryl compounds and uses thereof
PL2635299T3 (pl) * 2010-11-02 2020-03-31 The Trustees Of Columbia University In The City Of New York Sposoby leczenia zaburzeń utraty włosów
US9198911B2 (en) 2010-11-02 2015-12-01 The Trustees Of Columbia University In The City Of New York Methods for treating hair loss disorders
WO2012064706A1 (en) 2010-11-10 2012-05-18 Avila Therapeutics, Inc. Mutant-selective egfr inhibitors and uses thereof
JP6000273B2 (ja) * 2010-11-29 2016-09-28 オーエスアイ・ファーマシューティカルズ，エルエルシー 大環状キナーゼ阻害剤
EP2686323A1 (en) 2011-03-16 2014-01-22 Cephalon, Inc. Macrocyclic compounds as alk, fak and jak2 inhibitors
US8933066B2 (en) 2011-04-14 2015-01-13 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis C
WO2012141704A1 (en) * 2011-04-14 2012-10-18 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis c
AU2012299218A1 (en) 2011-08-19 2014-02-20 Merck Sharp & Dohme Corp. Crystal forms of a HCV protease inhibitor
US8629150B2 (en) 2011-09-28 2014-01-14 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis C
US8697706B2 (en) * 2011-10-14 2014-04-15 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis C
CA2853498A1 (en) 2011-10-28 2013-05-02 Celgene Avilomics Research, Inc. Methods of treating a bruton's tyrosine kinase disease or disorder
CN104185420B (zh) 2011-11-30 2017-06-09 埃默里大学 用于治疗或预防逆转录病毒和其它病毒感染的抗病毒jak抑制剂
US8916702B2 (en) 2012-02-06 2014-12-23 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis C
LT2822953T (lt) 2012-03-06 2017-04-10 Pfizer Inc. Makrocikliniai dariniai, skirti proliferacinių ligų gydymui
SMT201800571T1 (it) 2012-03-15 2019-01-11 Celgene Car Llc Sali di un inibitore di chinasi del recettore del fattore di crescita dell’epidermide
BR112014022789B1 (pt) 2012-03-15 2022-04-19 Celgene Car Llc Formas sólidas de um inibidor de quinase de receptor do fator de crescimento epidérmico, composição farmacêutica e usos do mesmo
PL2830662T3 (pl) * 2012-03-29 2019-02-28 The Trustees Of Columbia University In The City Of New York Sposoby leczenia zaburzeń utraty włosów
US9422311B2 (en) 2012-10-18 2016-08-23 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis C
WO2014072419A1 (en) 2012-11-08 2014-05-15 Universiteit Antwerpen Novel anti-hiv compounds
US8987264B2 (en) 2012-11-09 2015-03-24 Bristol-Myers Squibb Company 1,3,5-triazine derivatives of spiro bicyclic oxalamide-compounds for treatment of hepatitis C
US8987265B2 (en) 2012-11-09 2015-03-24 Bristol-Myers Squibb Company Substituted 1,3,5-triazine derivatives of fused bicyclic oxalamide compounds for treatment of Hepatitis C
US9126950B2 (en) 2012-12-21 2015-09-08 Celgene Avilomics Research, Inc. Heteroaryl compounds and uses thereof
CN104936949A (zh) 2013-01-25 2015-09-23 百时美施贵宝公司 用于治疗丙型肝炎的squaric衍生物
EP2948445B1 (en) 2013-01-25 2017-05-17 Bristol-Myers Squibb Company Guanidine derivatives for the treatment of hepatitis c
JP2016505069A (ja) * 2013-01-25 2016-02-18 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ Ｃ型肝炎の治療用のアンモニウム誘導体
EP2953954B1 (en) 2013-02-07 2017-11-15 Bristol-Myers Squibb Company Macrocyclic compounds as hcv entry inhibitors
JP2016507559A (ja) 2013-02-07 2016-03-10 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ Ｈｃｖエントリー阻害剤としての大環状分子
US9561228B2 (en) 2013-02-08 2017-02-07 Celgene Avilomics Research, Inc. ERK inhibitors and uses thereof
EP2958592A1 (en) 2013-02-22 2015-12-30 F. Hoffmann-La Roche AG Methods of treating cancer and preventing drug resistance
WO2014138199A1 (en) 2013-03-07 2014-09-12 Bristol-Myers Squibb Company Pyrimidine compounds for the treatment of hepatitis c
WO2014138239A1 (en) * 2013-03-07 2014-09-12 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis c
EP3587406B1 (en) 2013-03-13 2021-01-27 Forma Therapeutics, Inc. 2-hydroxy-1-{4-[(4-phenylphenyl)carbonyl]piperazin-1-yl}ethan-1-one derivatives and related compounds as fatty acid synthase (fasn) inhibitors for the treatment of cancer
US9492471B2 (en) 2013-08-27 2016-11-15 Celgene Avilomics Research, Inc. Methods of treating a disease or disorder associated with Bruton'S Tyrosine Kinase
CN105829293B (zh) * 2013-12-20 2018-11-09 中国人民解放军军事医学科学院毒物药物研究所 新型哌啶氨甲酰类化合物、制备方法及其用途
US9415049B2 (en) 2013-12-20 2016-08-16 Celgene Avilomics Research, Inc. Heteroaryl compounds and uses thereof
US10005760B2 (en) 2014-08-13 2018-06-26 Celgene Car Llc Forms and compositions of an ERK inhibitor
WO2016073847A2 (en) * 2014-11-07 2016-05-12 The Regents Of The University Of Michigan Inhibitors of myocardin-related transcription factor and serum response factor (mrtf/srf)-mediated gene transcription and methods for use of the same
EP3356373B1 (en) 2015-09-29 2020-02-19 Bayer Pharma Aktiengesellschaft Novel macrocyclic sulfondiimine compounds
CN108368129B (zh) 2015-10-08 2021-08-17 拜耳医药股份有限公司 改性大环化合物
WO2017060322A2 (en) 2015-10-10 2017-04-13 Bayer Pharma Aktiengesellschaft Ptefb-inhibitor-adc
GB2560713A (en) * 2017-03-20 2018-09-26 Eternygen Gmbh Inhibitor of citrate transporter
WO2018177889A1 (en) 2017-03-28 2018-10-04 Bayer Aktiengesellschaft Novel ptefb inhibiting macrocyclic compounds
ES2900199T3 (es) 2017-03-28 2022-03-16 Bayer Ag Novedosos compuestos macrocíclicos inhibidores de PTEFB
TWI767148B (zh) 2018-10-10 2022-06-11 美商弗瑪治療公司 抑制脂肪酸合成酶(fasn)
CN113382633A (zh) 2018-10-29 2021-09-10 福马治疗股份有限公司 (4-(2-氟-4-(1-甲基-1H-苯并[d]咪唑-5-基)苯甲酰基)哌嗪-1-基)(1-羟基环丙基)甲酮的固体形式
SG11202107080VA (en) 2019-01-11 2021-07-29 Naegis Pharmaceuticals Inc Leukotriene synthesis inhibitors
BR112021018168B1 (pt) 2019-03-21 2023-11-28 Onxeo Composição farmacêutica, combinação e kit compreendendo uma molécula dbait e um inibidor de quinase para o tratamento de câncer
US20220372135A1 (en) 2019-09-27 2022-11-24 Disc Medicine, Inc. Methods for treating myelofibrosis and related conditions
CA3159348A1 (en) 2019-11-08 2021-05-14 Inserm (Institut National De La Sante Et De La Recherche Medicale) Methods for the treatment of cancers that have acquired resistance to kinase inhibitors
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use
WO2021163627A1 (en) * 2020-02-14 2021-08-19 Salk Institute For Biological Studies Macrocyclic ulk1/2 inhibitors
MX2022010128A (es) * 2020-02-18 2023-01-04 Theseus Pharmaceuticals Inc Compuestos macrocíclicos y usos de estos.
CA3177830A1 (en) 2020-05-13 2021-11-18 Maria BECONI Anti-hemojuvelin (hjv) antibodies for treating myelofibrosis
CN113698408B (zh) * 2020-05-22 2025-07-25 武汉朗来科技发展有限公司 Jnk抑制剂、其药物组合物和用途
CN113735856A (zh) * 2020-05-29 2021-12-03 百极弘烨(南通)医药科技有限公司 大环jak抑制剂及其应用
CN113549113A (zh) * 2020-06-17 2021-10-26 广州百霆医药科技有限公司 一种含膦大环化合物及其制备方法与应用
CN114805371B (zh) * 2021-01-19 2024-05-24 江苏开元药业有限公司 含2-氨基嘧啶大环类化合物及其制备方法和用途
CN118139846A (zh) * 2021-09-23 2024-06-04 河南晟翔医药科技有限公司 一种egfr小分子抑制剂、含其的药物组合物及其用途
EP4450505A4 (en) * 2021-12-15 2025-07-02 Whan In Pharmaceutical Co Ltd MACROCYCLIC PYRIMIDINE DERIVATIVE, PREPARATION METHOD THEREOF, AND PHARMACEUTICAL COMPOSITION FOR PREVENTION OR TREATMENT OF NEURODEGENERATIVE DISEASE AND CONTAINING THIS DERIVATIVE AS ACTIVE INGREDIENT
CN114394974B (zh) * 2022-03-25 2022-12-06 中国药科大学 多取代三芳基大环化合物与应用
EP4568951A1 (en) * 2022-08-08 2025-06-18 Ajax Therapeutics, Inc. Heterocyclic amide and urea compounds as jak2 inhibitors
WO2024094171A1 (zh) * 2022-11-04 2024-05-10 江苏恒瑞医药股份有限公司 取代的氨基嘧啶类化合物、其制备方法及其在医药上的应用
CN116496234B (zh) * 2023-02-09 2024-09-13 江苏润安制药有限公司 一种盐酸乌拉地尔关键中间体的制备方法

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5521184A (en) 1992-04-03 1996-05-28 Ciba-Geigy Corporation Pyrimidine derivatives and processes for the preparation thereof
IL139811A0 (en) 1998-06-04 2002-02-10 Abbott Lab Cell adhesion-inhibiting antinflammatory compounds
PA8474101A1 (es) 1998-06-19 2000-09-29 Pfizer Prod Inc Compuestos de pirrolo [2,3-d] pirimidina
WO2000009495A1 (en) 1998-08-11 2000-02-24 Novartis Ag Isoquinoline derivatives with angiogenesis inhibiting activity
US6133031A (en) 1999-08-19 2000-10-17 Isis Pharmaceuticals Inc. Antisense inhibition of focal adhesion kinase expression
GB9905075D0 (en) 1999-03-06 1999-04-28 Zeneca Ltd Chemical compounds
PT1382339E (pt) 1999-12-10 2008-02-06 Pfizer Prod Inc Composições que contêm derivados de pirrolo[2,3-d]- pirimidina
WO2001047922A2 (en) 1999-12-24 2001-07-05 Aventis Pharma Limited Azaindoles
GB0004890D0 (en) 2000-03-01 2000-04-19 Astrazeneca Uk Ltd Chemical compounds
GB0011527D0 (en) 2000-05-12 2000-06-28 Unilever Plc Bleach catalyst and composition and method for bleaching a substrate
DE60105023T2 (de) 2000-06-28 2005-08-18 Smithkline Beecham P.L.C., Brentford Nassvermahlungsverfahren
MXPA04002243A (es) 2001-09-19 2004-06-29 Aventis Pharma Sa Compuestos quimicos.
CN101703509A (zh) 2001-10-30 2010-05-12 诺瓦提斯公司 作为flt3受体酪氨酸激酶活性抑制剂的星形孢菌素衍生物
AR037647A1 (es) 2002-05-29 2004-12-01 Novartis Ag Derivados de diarilurea utiles para el tratamiento de enfermedades dependientes de la cinasa de proteina
GB0215676D0 (en) 2002-07-05 2002-08-14 Novartis Ag Organic compounds
WO2004011422A1 (en) 2002-07-25 2004-02-05 University Of Florida Method for incorporation of pentafluorosulfanyl (sf5) substituents into aliphatic and aromatic compounds
DE10239042A1 (de) 2002-08-21 2004-03-04 Schering Ag Makrozyclische Pyrimidine, deren Herstellung und Verwendung als Arzneimittel
TWI335913B (en) 2002-11-15 2011-01-11 Vertex Pharma Diaminotriazoles useful as inhibitors of protein kinases
UA80767C2 (en) 2002-12-20 2007-10-25 Pfizer Prod Inc Pyrimidine derivatives for the treatment of abnormal cell growth
CA2515132C (en) 2003-02-07 2012-01-03 Vertex Pharmaceuticals Incorporated Heteroaryl substituted pyrroles useful as inhibitors of protein kinases
WO2004078682A2 (en) 2003-03-05 2004-09-16 Irm Llc Cyclic compounds and compositions as protein kinase inhibitors
DE60305634T2 (de) 2003-03-07 2006-09-21 Istituto Nazionale Per Lo Studio E La Cura Dei Tumori Anaplastisches Lymphoma Kinase Testverfahren, Reagenzien und Kompositionen davon
GB0305929D0 (en) 2003-03-14 2003-04-23 Novartis Ag Organic compounds
SE0301372D0 (sv) 2003-05-09 2003-05-09 Astrazeneca Ab Novel compounds
SE0301373D0 (sv) 2003-05-09 2003-05-09 Astrazeneca Ab Novel compounds
GB0316109D0 (en) 2003-07-09 2003-08-13 Dystar Textilfarben Gmbh & Co Water-soluble macrocyclic azacalixarenes
GB0316915D0 (en) 2003-07-18 2003-08-20 Glaxo Group Ltd Compounds
BRPI0412876A (pt) 2003-07-22 2006-10-03 Janssen Pharmaceutica Nv derivados de quinolinona como inibidores de c-fms quinase
DE10333183A1 (de) 2003-07-22 2005-02-17 Daimlerchrysler Ag Verfahren zum Betrieb eines Antriebsstranges für ein Kraftfahrzeug
AR045944A1 (es) 2003-09-24 2005-11-16 Novartis Ag Derivados de isoquinolina 1.4-disustituidas
JP2005220116A (ja) 2004-02-09 2005-08-18 Japan Science & Technology Agency １，３，５−トリアジン環を環構成要素として含むシクロファン型化合物、その製造方法、中間体及びその利用
PL1761540T3 (pl) 2004-05-13 2017-06-30 Icos Corporation Chinazolinony jako inhibitory ludzkiej kinazy 3-fosfatydyloinozytolu delta
BRPI0517887A (pt) 2004-11-24 2008-10-21 Novartis Ag combinações de inibidores de jaks
MY169441A (en) * 2004-12-08 2019-04-11 Janssen Pharmaceutica Nv 2,4, (4,6) pyrimidine derivatives
US20060194823A1 (en) 2004-12-22 2006-08-31 Georg Kettschau Sulfonamido-macrocycles as Tie2 inhibitors and the salts thereof, a pharmaceutical composition comprising these compounds, the method of preparing and the use thereof
EP1674470A1 (en) 2004-12-22 2006-06-28 Schering Aktiengesellschaft Sulfonamido-macrocycles as Tie2 inhibitors
EP1710246A1 (en) 2005-04-08 2006-10-11 Schering Aktiengesellschaft Sulfoximine-pyrimidine Macrocycles and the salts thereof, a process for making them, and their pharmaceutical use against cancer
US8778919B2 (en) 2005-06-30 2014-07-15 Janssen Pharmaceutica Nv Cyclic anilino—pyridinotriazines
EP1951729B1 (en) 2005-11-16 2014-06-25 Cell Therapeutics, Inc. Oxygen linked pyrimidine derivatives
TWI630207B (zh) 2005-12-13 2018-07-21 英塞特控股公司 作為傑納斯激酶（ＪＡＮＵＳ ＫＩＮＡＳＥ）抑制劑之經雜芳基取代之吡咯并〔２，３-ｂ〕吡啶及吡咯并〔２，３-ｂ〕嘧啶
EP1803723A1 (de) 2006-01-03 2007-07-04 Bayer Schering Pharma Aktiengesellschaft (2,4,9-triaza-1(2,4)-pyrimidina-3(1,3)-benzenacyclononaphan-3^4-yl)-sulfoximid derivate als selektive inhibitoren der aurora kinase zur behandlung von krebs
EP1873159A1 (en) 2006-06-21 2008-01-02 Bayer Schering Pharma Aktiengesellschaft Substituted sulphonamido-macrocycles as Tie2 inhibitors and salts thereof, pharmaceutical compositions comprising same, methods of preparing same and uses of same
EP1870416A1 (en) 2006-06-21 2007-12-26 Bayer Schering Pharma Aktiengesellschaft Sulphonamido-macrocycles as tie2 inhibitors

Similar Documents

Publication Publication Date Title
JP2011518836A5 (enExample)
JP5759470B2 (ja) オレキシン受容体調節因子としての二置換オクタヒドロピロロ［３，４−ｃ］ピロール
US9855269B2 (en) Aminoquinazoline and pyridopyrimidine derivatives
US8871753B2 (en) Macrocyclic compounds and their use as kinase inhibitors
JP6170121B2 (ja) オレキシン受容体調節因子としての縮合複素環式化合物
DE602004011401T2 (de) Benzazepinderivate als histamin-h3-antagonisten
JP5823518B2 (ja) ブルトン型チロシンキナーゼの阻害剤
CN112638373A (zh) 细胞周期蛋白依赖性激酶抑制剂
RU2662443C2 (ru) Имидазопиридазины
AU2022349569A1 (en) Pyridine derivative and use thereof
JP2013503846A (ja) ベンズイミダゾール誘導体
JP2010513444A5 (enExample)
CA2664810A1 (en) Substituted sulfonamide derivatives
JP2017516826A (ja) 炎症性および自己免疫性の病気の処置のためのｍｔｈ１阻害剤
JP2015522057A (ja) ＲＯＲｃモジュレーターとしてのアリールスルタム誘導体
AU2006236387A1 (en) Subtituted heteroaryl CB1 antagonists
JP2019519484A5 (enExample)
EP2440204A1 (en) Nicotinamide compounds useful as kinase modulators
JP2011503194A5 (enExample)
WO2011050200A1 (en) Fused heterocyclic compounds as orexin receptor modulators
AU2014248763A1 (en) Substituted piperidine compounds and their use as orexin receptor modulators
JP2018520201A5 (enExample)
AU2004273771A1 (en) 3-heterocyclyl-indole derivatives as inhibitors of glycogen synthase kinase-3 (GSK-3)
US20090227555A2 (en) Novel Pyridine Compounds
JP6304492B2 (ja) トリアジノン化合物及びｔ型カルシウムチャネル阻害剤